Literature DB >> 14605056

Tumor size predicts survival within stage IA non-small cell lung cancer.

Jeffrey L Port1, Michael S Kent, Robert J Korst, Daniel Libby, Mark Pasmantier, Nasser K Altorki.   

Abstract

STUDY
OBJECTIVES: The basic premise of CT screening is that size is an important determinant of survival in lung cancer. We sought to examine this hypothesis within stage IA non-small cell lung cancer (NSCLC).
METHODS: A retrospective analysis of all patients with pathologically confirmed stage IA NSCLC resected from 1991 to 2001 was conducted. All but seven patients underwent anatomic lung resection and mediastinal lymph node dissection. Kaplan-Meier survival analysis was performed to estimate the 5-year overall and disease-specific survival probability stratified by tumor size. The influence of age, gender, histology, and tumor size on survival was also analyzed using a Cox proportional hazards regression model.
RESULTS: There were 244 patients (mean age, 66.7 years; 45.1% were men). Lobectomy was performed in 229 patients, segmentectomy in 8 patients, and wedge resection in 7 patients. Operative mortality was 0.4%. Histologic breakdown was as follows: adenocarcinoma (59.4%), squamous (18.9%), bronchoalveolar (15.2%), large cell (4.5%), and poorly differentiated (2.0%). The median follow-up time for all patients was 2.6 years. The 5-year survival probability for all patients was 71.1% (95% confidence interval [CI], 63.6 to 78.6%). For 161 patients with tumor sizes < or = 2.0 cm, the 5-year survival probability was 77.2% (95% CI, 68.6 to 85.8%) in comparison with 60.3% (95% CI, 46.7 to 73.8%) in 83 patients with tumor size > 2.0 cm (p = 0.03 by log-rank test). The overall 5-year disease-specific survival was 74.9% (95% CI, 67.6 to 82.2%). Disease-specific survival was 81.4% (95% CI, 73.3 to 89.4%) for patients with tumors < or = 2.0 cm and 63.4% (95% CI, 49.6 to 77.1%) for patients with tumors > 2.0 cm.
CONCLUSIONS: These data suggest that size within stage IA is an important predictor of survival and that further substaging should be considered.

Entities:  

Mesh:

Year:  2003        PMID: 14605056     DOI: 10.1378/chest.124.5.1828

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  38 in total

1.  Diagnostic yield of preoperative computed tomography imaging and the importance of a clinical decision for lung cancer surgery.

Authors:  Shuichi Sato; Teruaki Koike; Yasushi Yamato; Katsuo Yoshiya; Nozomu Motono; Mariko Takeshige; Naoya Koizumi; Keiichi Homma; Hiroko Tsukada; Akira Yokoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-09-22

2.  Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results.

Authors:  Olivier Gevaert; Jiajing Xu; Chuong D Hoang; Ann N Leung; Yue Xu; Andrew Quon; Daniel L Rubin; Sandy Napel; Sylvia K Plevritis
Journal:  Radiology       Date:  2012-06-21       Impact factor: 11.105

3.  Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.

Authors:  Bing Chen; Wenjie Xia; Zhongqiu Wang; Heng Zhao; Xiaofei Li; Lunxu Liu; Yang Liu; Jian Hu; Xiangning Fu; Yin Li; Yijun Xu; Deruo Liu; Haiying Yang; Lin Xu; Feng Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-19       Impact factor: 4.553

4.  Radio-guided thoracoscopic surgery (RGTS) of small pulmonary nodules.

Authors:  Marcello Carlo Ambrogi; Franca Melfi; Carmelina Zirafa; Marco Lucchi; Annalisa De Liperi; Giuliano Mariani; Olivia Fanucchi; Alfredo Mussi
Journal:  Surg Endosc       Date:  2011-10-20       Impact factor: 4.584

5.  Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy.

Authors:  Marco Spadafora; Leonardo Pace; Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01       Impact factor: 9.236

6.  Nonintubated thoracoscopic lobectomy plus lymph node dissection following segmentectomy for central type pulmonary masses.

Authors:  Wenlong Shao; Wei Wang; Weiqiang Yin; Zhihua Guo; Guilin Peng; Ying Chen; Jianxing He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

7.  Lobectomy and limited resection in small-sized peripheral non-small cell lung cancer.

Authors:  Terumoto Koike; Teruaki Koike; Seijiro Sato; Takehisa Hashimoto; Tadashi Aoki; Katsuo Yoshiya; Yasushi Yamato; Takehiro Watanabe; Kohei Akazawa; Shin-Ichi Toyabe; Masanori Tsuchida
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

8.  Port-access thoracoscopic anatomical lung subsegmentectomy.

Authors:  Hirohisa Kato; Hiroyuki Oizumi; Takashi Inoue; Eiichi Oba; Ken Nakamura; Jun Hayashi; Hikaru Watarai; Takumi Yasumoto; Mitsuaki Sadahiro
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-20

9.  Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice.

Authors:  Fekadu Kassie; Stephen Kalscheuer; Ilze Matise; Linan Ma; Tamene Melkamu; Pramod Upadhyaya; Stephen S Hecht
Journal:  Carcinogenesis       Date:  2009-07-22       Impact factor: 4.944

10.  Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.

Authors:  Zhenbin Chen; Jinong Feng; Carolyn H Buzin; Qiang Liu; Lawrence Weiss; Kemp Kernstine; George Somlo; Steve S Sommer
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.